{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:23:25Z","timestamp":1787063005839,"version":"build-2736575974"},"reference-count":22,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["JAMA Facial Plast Surg"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Although malignancy is an established risk factor for venous thromboembolism (VTE), the risk of VTE specifically in patients with keratinocyte carcinoma (KC) has not been previously studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the risk of VTE in patients with KC compared with patients not diagnosed with cancer and with patients diagnosed with common malignant neoplasms associated with VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>Population-based retrospective analysis of patient insurance claims made between January 1, 2007, and December 31, 2014, from the Truven MarketScan Commercial and Medicare Supplemental Databases. Patients treated across the United States were divided into 3 cohorts: patients with KC, patients with pancreatic cancer or acute myelogenous leukemia who are thus at high risk for VTE, and patients without a history of common malignant neoplasms. Patients were excluded from the KC cohort if they had a history of another type of cancer. Data were analyzed between April 1, 2017, and January 15, 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Diagnosis of VTE within 1 year following the index date (for the KC and high-risk cohorts, the date of the initial diagnosis of cancer; for the control cohort, the date following 365 days of continuous insurance enrollment). Logistic regression was used to assess the risk of VTE in the KC cohort compared with the high-risk and control cohorts before and after matching across patient characteristics and known risk factors for VTE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 5\u2009753\u2009613 potentially eligible patients, the final sample consisted of 740\u2009246 patients (12.8%) across 3 cohorts. Of the 740\u2009246 study participants, 417\u2009839 were in the KC cohort (223\u2009986 [53.6%] men, mean [SD] age, 64.2 [13.6] years); 314\u2009736 were in the control cohort (135\u2009203 [43.0%] men, 42.9 [15.2] years); and 7671 were in the high-risk cohort (3502 [45.7%] men, 59.4 [14.4] years) The risk of VTE in the KC cohort was lower compared with the high-risk cohort in univariable analysis (odds ratio [OR], 0.22; 95% CI, 0.20-0.23;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), multivariable analysis (OR, 0.29; 95% CI, 0.26-0.32;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), and after matching across patient characteristics and known risk factors (OR, 0.52; 95% CI, 0.35-0.78;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.001). The risk of VTE in the KC cohort was higher in the univariable analysis (OR, 2.31; 95% CI, 2.23-2.41;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), lower in the multivariable analysis (OR, 0.85; 95% CI, 0.80-0.90;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001), and not different after matching of patient characteristics and risk factors (OR, 0.95; 95% CI, 0.89-1.01;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.08) than that of the control cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this study provided no evidence supporting the increased risk of VTE in the KC cohort compared with the control cohort. Given the inherent risks of chemoprophylaxis, the need for prophylactic anticoagulation in patients with KC who are scheduled for surgery should be carefully considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jamanetwork.com\/journals\/jamafacialplasticsurgery\/pages\/instructions-for-authors\/#SecLevelofEvidence\/Ethnicity\">NA<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamafacial.2018.0331","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T12:32:06Z","timestamp":1527165126000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk of Venous Thromboembolism in Patients With Keratinocyte Carcinoma"],"prefix":"10.1177","volume":"20","author":[{"given":"Shannon F.","family":"Rudy","sequence":"first","affiliation":[{"name":"Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology\u2013Head and Neck Surgery, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Li","sequence":"additional","affiliation":[{"name":"Medical student, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami P.","family":"Moubayed","sequence":"additional","affiliation":[{"name":"Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology\u2013Head and Neck Surgery, Stanford University School of Medicine, Stanford, California"},{"name":"Division of Otolaryngology\u2013Head and Neck Surgery, Department of Surgery, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam P.","family":"Most","sequence":"additional","affiliation":[{"name":"Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology\u2013Head and Neck Surgery, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.14.1711"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807093390207"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(16)30108-6"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01804.x"},{"issue":"3","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejca.2005.09.013","article-title":"High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients","volume":"42","author":"Blom JW","year":"2006","unstructured":"Blom JW, , Osanto S, , Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer. 2006; 42(3):410-414. doi:10.1016\/j.ejca.2005.09.013, 16321518","journal-title":"Eur J Cancer"},{"key":"e_1_3_1_7_2","first-page":"304","article-title":"Clinical assessment of venous thromboembolic risk in surgical patients","volume":"17","author":"Caprini JA","year":"1991","unstructured":"Caprini JA, , Arcelus JI, , Hasty JH, , Tamhane AC, , Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991; 17(suppl 3):304-312. 1754886","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Gould MK","year":"2012","unstructured":"Gould MK, , Garcia DA, , Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2)(suppl):e227S-e277S. doi:10.1378\/chest.11-2297, 22315263","journal-title":"Chest"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2015.1841"},{"issue":"7","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1076029615575344","article-title":"Evaluation of VTE prophylaxis in an educational hospital: comparison between the institutional guideline (Caprini 2006) and the ACCP guideline (ninth edition)","volume":"22","author":"Gharaibeh L","year":"2016","unstructured":"Gharaibeh L, , Albsoul-Younes A, , Younes N. Evaluation of VTE prophylaxis in an educational hospital: comparison between the institutional guideline (Caprini 2006) and the ACCP guideline (ninth edition). Clin Appl Thromb\/Hemost. 2016; 22(7):627-632. doi:10.1177\/1076029615575344","journal-title":"Clin Appl Thromb\/Hemost"},{"key":"e_1_3_1_11_2","unstructured":"Caprini DVT risk assessment. Venous Resource Center. https:\/\/venousdisease.com\/caprini-dvt-risk-assessment\/. Accessed August 20 2017."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_3_1_13_2","unstructured":"ICD-9-CM index to diseases and injuries addenda effective October 1 2011 (FY12). https:\/\/www.cdc.gov\/nchs\/data\/icd\/icd-9-cmindexaddendafy12.pdf. Accessed June 1 2017."},{"issue":"2","key":"e_1_3_1_14_2","first-page":"135","article-title":"Thromboembolism and anticoagulation in pancreatic cancer","volume":"14","author":"Habib M","year":"2013","unstructured":"Habib M, , Saif MW. Thromboembolism and anticoagulation in pancreatic cancer. JOP. 2013; 14(2):135-137. doi:10.6092\/1590-8577\/1480, 23474555","journal-title":"JOP"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175745"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.08.003"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31819432e5"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02237127"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.141.8.790"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318295870e"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06018.x"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24758"}],"updated-by":[{"DOI":"10.1001\/jamafacial.2017.1549","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000}}],"container-title":["JAMA Facial Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1001\/jamafacial.2018.0331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1001\/jamafacial.2018.0331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1001\/jamafacial.2018.0331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:25:53Z","timestamp":1777443953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1001\/jamafacial.2018.0331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1001\/jamafacial.2018.0331"],"URL":"https:\/\/doi.org\/10.1001\/jamafacial.2018.0331","relation":{},"ISSN":["2168-6076","2168-6092"],"issn-type":[{"value":"2168-6076","type":"print"},{"value":"2168-6092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}